Dose consolidation and quantity limit initiatives decreased utilization and cost outcomes for select mental health drugs in a fee-for-service Medicaid environment.
Gary R. Tataronis, MS
Advertisement
Articles by Gary R. Tataronis, MS
Advertisement
Latest Updated Articles
- Cost and Utilization Outcomes Associated With a Dosage Consolidation and Quantity Limits Program
Published: October 27th 2010 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Grants Interchangeability Designation to Denosumab Biosimilars Stoboclo and Osenvelt
2
Because Ned Said: America’s Growing Pharmacy Deserts Are Leaving Patients High and Dry
3
Meeting Patients Where They Are: How Pharmacists Are Helping People Stay on Track With Schizophrenia Treatment
4
Denosumab Biosimilars Conexxence and Bomyntra Receive Interchangeability Designation
5
